Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans-Reference-Cited by-同舟云学术

Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans

Published:2013-05-24 Issue:2 Volume:346 Page:219-228
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Evans Erica K.,Tester Richland,Aslanian Sharon,Karp Russell,Sheets Michael,Labenski Matthew T.,Witowski Steven R.,Lounsbury Heather,Chaturvedi Prasoon,Mazdiyasni Hormoz,Zhu Zhendong,Nacht Mariana,Freed Martin I.,Petter Russell C.,Dubrovskiy Alex,Singh Juswinder,Westlin William F.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference44 articles.

1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2. Regulation of Btk by Src family tyrosine kinases;Afar;Mol Cell Biol,1996

3. BLNK mediates Syk-dependent Btk activation

4. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

5. R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

2. A Probe-Free Occupancy Assay to Assess a Targeted Covalent Inhibitor of Receptor Tyrosine-Protein Kinase erbB-2;ACS Pharmacology & Translational Science;2024-08-01

3. A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology;Clinical Pharmacology & Therapeutics;2024-07-28

4. A Comprehensive Review of Small-Molecule Inhibitors Targeting Bruton Tyrosine Kinase: Synthetic Approaches and Clinical Applications;Molecules;2023-12-11

5. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study;The Journal of Clinical Pharmacology;2023-09-29